MRI-coupled Fluorescence Tomography Quantifies EGFR Activity in Brain Tumors

Scott C. Davis, Kimberley S. Samkoe, Julia A. O'Hara, Summer Gibbs, Hannah L. Payne, P. Jack Hoopes, Keith D. Paulsen, Brian W. Pogue

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Rationale and Objectives: This report demonstrates the diagnostic potential of magnetic resonance imaging (MRI)-coupled fluorescence molecular tomography (FMT) to determine epidermal growth factor receptor (EGFR) status in brain cancer. Materials and Methods: Two orthotopic glioma xenograft models were used in this study: one represented high EGFR expression and the other low expression. Nude mice were inoculated with cells from either one of the tumor lines or were used in a sham surgery control group. Animals were imaged using a unique MRI-FMT scanner 48 hours after intravenous injection of a near-infrared fluorophore bound to epidermal growth factor (EGF) ligand. Coronal images of fluorescence activity of the injected dye in the mouse brain were recovered using the MRI images as anatomical templates. Results: In vivo images of fluorescence activity showed significant differences between animal populations, an observation confirmed by receiver operating characteristic analysis that revealed 100% sensitivity and specificity between animal groups implanted with EGFR(+) and EGFR(-) tumor lines. Similar performance was observed between EGFR(+) and sham surgery control animals. Conclusions: This preclinical study suggests that MRI-FMT with fluorescent EGF provides excellent discrimination between tumors based on EGFR status. Reliable quantification of receptor status using minimally invasive techniques would be an important innovation for investigating new and existing cancer treatments that target these cellular mechanisms in research animals, and may be applied to identify receptor amplification in human brain cancer patients. This study represents the first systematic multianimal validation of receptor-specific imaging using MRI-guided fluorescence tomography.

Original languageEnglish (US)
Pages (from-to)271-276
Number of pages6
JournalAcademic Radiology
Volume17
Issue number3
DOIs
StatePublished - Mar 2010
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Brain Neoplasms
Fluorescence
Tomography
Magnetic Resonance Imaging
Epidermal Growth Factor
Neoplasms
Heterografts
Nude Mice
ROC Curve
Glioma
Intravenous Injections
Coloring Agents
Observation
Ligands
Sensitivity and Specificity
Control Groups
Brain
Population

Keywords

  • Epidermal growth factor receptor
  • fluorescence molecular tomography
  • glioma
  • MRI
  • multi-modal imaging
  • optical spectroscopy
  • tissue diagnosis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Davis, S. C., Samkoe, K. S., O'Hara, J. A., Gibbs, S., Payne, H. L., Hoopes, P. J., ... Pogue, B. W. (2010). MRI-coupled Fluorescence Tomography Quantifies EGFR Activity in Brain Tumors. Academic Radiology, 17(3), 271-276. https://doi.org/10.1016/j.acra.2009.11.001

MRI-coupled Fluorescence Tomography Quantifies EGFR Activity in Brain Tumors. / Davis, Scott C.; Samkoe, Kimberley S.; O'Hara, Julia A.; Gibbs, Summer; Payne, Hannah L.; Hoopes, P. Jack; Paulsen, Keith D.; Pogue, Brian W.

In: Academic Radiology, Vol. 17, No. 3, 03.2010, p. 271-276.

Research output: Contribution to journalArticle

Davis, SC, Samkoe, KS, O'Hara, JA, Gibbs, S, Payne, HL, Hoopes, PJ, Paulsen, KD & Pogue, BW 2010, 'MRI-coupled Fluorescence Tomography Quantifies EGFR Activity in Brain Tumors', Academic Radiology, vol. 17, no. 3, pp. 271-276. https://doi.org/10.1016/j.acra.2009.11.001
Davis, Scott C. ; Samkoe, Kimberley S. ; O'Hara, Julia A. ; Gibbs, Summer ; Payne, Hannah L. ; Hoopes, P. Jack ; Paulsen, Keith D. ; Pogue, Brian W. / MRI-coupled Fluorescence Tomography Quantifies EGFR Activity in Brain Tumors. In: Academic Radiology. 2010 ; Vol. 17, No. 3. pp. 271-276.
@article{2be2376ce6eb4df69aea915ebbf9c378,
title = "MRI-coupled Fluorescence Tomography Quantifies EGFR Activity in Brain Tumors",
abstract = "Rationale and Objectives: This report demonstrates the diagnostic potential of magnetic resonance imaging (MRI)-coupled fluorescence molecular tomography (FMT) to determine epidermal growth factor receptor (EGFR) status in brain cancer. Materials and Methods: Two orthotopic glioma xenograft models were used in this study: one represented high EGFR expression and the other low expression. Nude mice were inoculated with cells from either one of the tumor lines or were used in a sham surgery control group. Animals were imaged using a unique MRI-FMT scanner 48 hours after intravenous injection of a near-infrared fluorophore bound to epidermal growth factor (EGF) ligand. Coronal images of fluorescence activity of the injected dye in the mouse brain were recovered using the MRI images as anatomical templates. Results: In vivo images of fluorescence activity showed significant differences between animal populations, an observation confirmed by receiver operating characteristic analysis that revealed 100{\%} sensitivity and specificity between animal groups implanted with EGFR(+) and EGFR(-) tumor lines. Similar performance was observed between EGFR(+) and sham surgery control animals. Conclusions: This preclinical study suggests that MRI-FMT with fluorescent EGF provides excellent discrimination between tumors based on EGFR status. Reliable quantification of receptor status using minimally invasive techniques would be an important innovation for investigating new and existing cancer treatments that target these cellular mechanisms in research animals, and may be applied to identify receptor amplification in human brain cancer patients. This study represents the first systematic multianimal validation of receptor-specific imaging using MRI-guided fluorescence tomography.",
keywords = "Epidermal growth factor receptor, fluorescence molecular tomography, glioma, MRI, multi-modal imaging, optical spectroscopy, tissue diagnosis",
author = "Davis, {Scott C.} and Samkoe, {Kimberley S.} and O'Hara, {Julia A.} and Summer Gibbs and Payne, {Hannah L.} and Hoopes, {P. Jack} and Paulsen, {Keith D.} and Pogue, {Brian W.}",
year = "2010",
month = "3",
doi = "10.1016/j.acra.2009.11.001",
language = "English (US)",
volume = "17",
pages = "271--276",
journal = "Academic Radiology",
issn = "1076-6332",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - MRI-coupled Fluorescence Tomography Quantifies EGFR Activity in Brain Tumors

AU - Davis, Scott C.

AU - Samkoe, Kimberley S.

AU - O'Hara, Julia A.

AU - Gibbs, Summer

AU - Payne, Hannah L.

AU - Hoopes, P. Jack

AU - Paulsen, Keith D.

AU - Pogue, Brian W.

PY - 2010/3

Y1 - 2010/3

N2 - Rationale and Objectives: This report demonstrates the diagnostic potential of magnetic resonance imaging (MRI)-coupled fluorescence molecular tomography (FMT) to determine epidermal growth factor receptor (EGFR) status in brain cancer. Materials and Methods: Two orthotopic glioma xenograft models were used in this study: one represented high EGFR expression and the other low expression. Nude mice were inoculated with cells from either one of the tumor lines or were used in a sham surgery control group. Animals were imaged using a unique MRI-FMT scanner 48 hours after intravenous injection of a near-infrared fluorophore bound to epidermal growth factor (EGF) ligand. Coronal images of fluorescence activity of the injected dye in the mouse brain were recovered using the MRI images as anatomical templates. Results: In vivo images of fluorescence activity showed significant differences between animal populations, an observation confirmed by receiver operating characteristic analysis that revealed 100% sensitivity and specificity between animal groups implanted with EGFR(+) and EGFR(-) tumor lines. Similar performance was observed between EGFR(+) and sham surgery control animals. Conclusions: This preclinical study suggests that MRI-FMT with fluorescent EGF provides excellent discrimination between tumors based on EGFR status. Reliable quantification of receptor status using minimally invasive techniques would be an important innovation for investigating new and existing cancer treatments that target these cellular mechanisms in research animals, and may be applied to identify receptor amplification in human brain cancer patients. This study represents the first systematic multianimal validation of receptor-specific imaging using MRI-guided fluorescence tomography.

AB - Rationale and Objectives: This report demonstrates the diagnostic potential of magnetic resonance imaging (MRI)-coupled fluorescence molecular tomography (FMT) to determine epidermal growth factor receptor (EGFR) status in brain cancer. Materials and Methods: Two orthotopic glioma xenograft models were used in this study: one represented high EGFR expression and the other low expression. Nude mice were inoculated with cells from either one of the tumor lines or were used in a sham surgery control group. Animals were imaged using a unique MRI-FMT scanner 48 hours after intravenous injection of a near-infrared fluorophore bound to epidermal growth factor (EGF) ligand. Coronal images of fluorescence activity of the injected dye in the mouse brain were recovered using the MRI images as anatomical templates. Results: In vivo images of fluorescence activity showed significant differences between animal populations, an observation confirmed by receiver operating characteristic analysis that revealed 100% sensitivity and specificity between animal groups implanted with EGFR(+) and EGFR(-) tumor lines. Similar performance was observed between EGFR(+) and sham surgery control animals. Conclusions: This preclinical study suggests that MRI-FMT with fluorescent EGF provides excellent discrimination between tumors based on EGFR status. Reliable quantification of receptor status using minimally invasive techniques would be an important innovation for investigating new and existing cancer treatments that target these cellular mechanisms in research animals, and may be applied to identify receptor amplification in human brain cancer patients. This study represents the first systematic multianimal validation of receptor-specific imaging using MRI-guided fluorescence tomography.

KW - Epidermal growth factor receptor

KW - fluorescence molecular tomography

KW - glioma

KW - MRI

KW - multi-modal imaging

KW - optical spectroscopy

KW - tissue diagnosis

UR - http://www.scopus.com/inward/record.url?scp=75749147617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749147617&partnerID=8YFLogxK

U2 - 10.1016/j.acra.2009.11.001

DO - 10.1016/j.acra.2009.11.001

M3 - Article

VL - 17

SP - 271

EP - 276

JO - Academic Radiology

JF - Academic Radiology

SN - 1076-6332

IS - 3

ER -